[Correction of urodynamic disorders in women with obstructive urination].
From a position of urodynamic evaluation, obstructive urination represents a violation of the phase of urinary bladder emptying. The study was aimed to evaluation of urodynamic parameters in women with obstructive urination on a background of conservative treatment. The study included 40 women with obstructive urination aged 26 to 72 years. All patients received alpha-adrenoblocker Omnic Okas (tamsulosin) at a dose 0.4 mg once a day in the morning for 3 months. Initially, a visual assessment of uroflougramm revealed curves tipical for the obstructive type of urination. Quantitative parameters showed a decrease in the maximum urine flow rate and lengthening the time of urination. Treatment with alpha-adrenoblocker contributed to shortening the time of urination, and increased maximum urine flow rate. Before treatment, ultrasound examination revealed the presence of residual urine volume of 60-210 mL (mean 129 ml) after urination in 32 (80%) patients. After treatment, presence of residual urine volume of 50-90 ml (mean 65 ml) was noted only in 9 (22.5%) patients. It is concluded that the selective alpha-adrenoblocker Omnic-Okas neutralizes the effect mediated by alpha-adrenoceptors in the area of the bladder neck and proximal urethra, and contribute to the normal detrusor contraction, and therefore, eliminates the functional obstruction, while significantly improving the quality of life of patients.
A I
AI
Neĭmark
M V
MV
Razdorskaia
Iu S
IuS
Kondrat'eva
N I
NI
Muzalevskaia
D058668:Adrenergic alpha-1 Receptor Antagonists / Q000008:administration & dosage*; D000328:Adult; D000368:Aged; D005260:Female; D006801:Humans; D008875:Middle Aged; D013449:Sulfonamides / Q000008:administration & dosage*; D000077409:Tamsulosin; D014521:Urethra / Q000503:physiopathology; D001743:Urinary Bladder / Q000503:physiopathology; D016055:Urinary Retention / Q000188:drug therapy* / Q000503:physiopathology*; D014554:Urination / Q000187:drug effects*; D014563:Urodynamics / Q000187:drug effects*
D058668:Adrenergic alpha-1 Receptor Antagonists; D013449:Sulfonamides; D000077409:Tamsulosin